Dermatology

Login Register

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Parthika Patel

M. Pharm (Pharmaceutics)

Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Home

Parthika Patel

Articles By : Parthika Patel

Lupin gets 4 USFDA observations for Pune Biotech facility

Lupin to Conduct BE Study for Synthetic Semaglutide Tablets in 3 Strengths

Parthika Patel15 Aug 2025 3:02 PM IST

New Delhi: Lupin Limited has received the green light from the Subject Expert Committee (SEC) under the Endocrinology & Metabolism division of the...

Zydus Lifesciences Reports Rs 6,573.7 Cr Revenue in Q1 FY26, Net Profit Rises 3%

Parthika Patel14 Aug 2025 2:00 PM IST

New Delhi: Zydus Lifesciences Limited has announced its unaudited consolidated financial results for the first quarter ended June 30, 2025, reporting...

CDSCO Tightens RTI Appeal Timelines, Division Heads to Face Penalties for Lapses

CDSCO Launches One-Year Online Dual Use NOC System for Bulk Drug Imports

Parthika Patel13 Aug 2025 6:07 PM IST

New Delhi: The Central Drugs Standard Control Organisation (CDSCO) has introduced a new online Dual Use No Objection Certificate (NOC) system on its...

UCPMP 2024: Govt Details Stricter Rules to Curb Gifts, Incentives from Pharma to Doctors

Parthika Patel12 Aug 2025 2:28 PM IST

New Delhi: During the last five years, a total of seven complaints were received under the Uniform Code of Pharmaceutical Marketing Practices (UCPMP),...

Chemists Body Warns of 55% Rise in Drug Abuse, Calls for Ban on 10-Minute Prescription Drug Delivery

Draft Rules Set to Regulate Online Sale of Addictive Painkillers, Psychotropic Drugs: Govt

Parthika Patel12 Aug 2025 1:37 PM IST

New Delhi: The Union Government has informed the Lok Sabha that draft rules have been issued to comprehensively regulate the online sale of medicines,...

CDSCO Cancels Registration Certificate of G3 Medical Systems for Import of Allergan Cosmetics

CDSCO Cancels Cosmetic Import Registration of Indian Agent for Proteos Biotech

Parthika Patel11 Aug 2025 3:45 PM IST

New Delhi: The Central Drugs Standard Control Organisation (CDSCO) has cancelled the Cosmetic Registration Certificate No. RC/COS-003595, held by NKG...

CDSCO Panel Accepts Glenmark's Apremilast Trial Report, Seeks 2-Year PSUR Data

Parthika Patel10 Aug 2025 1:00 PM IST

New Delhi: Glenmark Pharmaceuticals Limited has received approval from the Subject Expert Committee (SEC), functioning under the Central Drugs...

Intas Pharma Told to Revise Phase I, III Pembrolizumab Trial Protocol

Intas Pharma Gets Expert Panel Nod For PMS Data On Tofacitinib Ointment In Atopic Dermatitis

Parthika Patel9 Aug 2025 11:30 AM IST

New Delhi: Intas Pharma has received approval from the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO)...

Abbott to Conduct BE Study for Carbimazole 15 mg, Trial Waiver Granted In India

Parthika Patel8 Aug 2025 2:34 PM IST

New Delhi: Abbott Healthcare Pvt. Ltd has received the green signal from the Subject Expert Committee (SEC) under the Central Drugs Standard Control...

Dr Reddy's Gets CDSCO Panel Approval To Begin Phase III Trial of Tapinarof Cream

Parthika Patel7 Aug 2025 11:41 PM IST

New Delhi: Dr. Reddy's Laboratories Limited has received approval from the Subject Expert Committee (SEC) under CDSCO to conduct a Phase III clinical...

No Waiver for Faricimab: CDSCO Panel Asks Roche to Conduct Phase III Trial in India

Parthika Patel6 Aug 2025 3:34 PM IST

New Delhi: Roche Products (India) Pvt Ltd has been directed by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation...

Novartis Loses India Patent on Heart Failure Drug Vymada

Novartis Told to Revise Protocol, Justify Sample Size in ITU512 Clinical Trial Proposal

Parthika Patel3 Aug 2025 9:30 AM IST

New Delhi: Novartis Healthcare Private Limited has been directed by the Subject Expert Committee (SEC) functional under the Central Drugs Standard...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok